---
title: "Elotuzumab"
slug: "elotuzumab"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Monoclonal Antibodies]]

# Elotuzumab

- Mechanism: Binds to the signaling lymphocytic activation molecule family member 7 (SLAMF7)
- Dosing:
  - Cycle 1-2 given in combination w/ lenalidomide & dexamethasone or pomalidomide & dexamethasone: 10 mg/kg IV once weekly on a 28-d cycle;
  - cycle 3 & more given in combination w/ lenalidomide & dexamethasone: 10 mg/kg IV every 2 wks of a 28-d cycle;
  - cycle 3 & more given in combination w/ pomalidomide & dexamethasone: 20 mg/kg IV every 4 wks of a 28-d cycle. Withhold or discontinue tx for toxicity (hepatic & infusion rxns)
- PK/PD: T1/2 âˆ¼82 d
- AEs:
  - Fatigue,
  - high blood pressure,
  - diarrhea,
  - â†“ Ca,
  - leukopenia,
  - thrombocytopenia,
  - â†‘ alk phos,
  - hepatotoxicity,
  - â†‘ blood glucose,
  - infxn,
  - infusion rxns,
  - 2Â° malignancy
- DDI: No known pathways of metabolism, avoid live & inactivated vaccines
- Clinical pearls:
  - Antiviral ppx should be started prior to tx,
  - requires premedication,
  - can interfere w/ assays for M-protein monitoring
